PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH PHOSPHODIESTERASE-5 INHIBITOR THERAPY

Retin Cases Brief Rep. 2021 Sep 1;15(5):519-522. doi: 10.1097/ICB.0000000000000839.

Abstract

Purpose: To present an atypical case of paracentral acute middle maculopathy occurred upon awakening in the morning within hours after phosphodiesterase-5 (PDE-5) inhibitor consumption at bedtime.

Methods: Multimodal retinal imaging findings, including fluorescein angiography, spectral domain optical coherence tomography, optical coherence tomography angiography, and microperimetry of a particular case of paracentral acute middle maculopathy lesion that follow the distribution of the cilioretinal artery.

Results: A 52-year-old healthy man presented with an acute paracentral scotoma in his left eye upon awakening in the morning, after the use of a PDE-5 inhibitor pill the previous night. Spectral domain optical coherence tomography illustrated a hyperreflective band-like lesion at the level of the inner nuclear layer, consistent with a diagnosis of paracentral acute middle maculopathy, along the course of the cilioretinal artery that appeared normally perfused with fluorescein angiography. Optical coherence tomography angiography showed a perfusion deficit and capillary pruning of the retinal deep capillary plexus, with preserved intermediate capillary plexus, that colocalized with the paracentral scotoma confirmed with microperimetry.

Conclusion: To our knowledge, this is the first report of paracentral acute middle maculopathy after the use of PDE-5 inhibitor. Nocturnal arterial hypotension exacerbated by the vasodilatory effect of the PDE-5 inhibitor may have caused transient cilioretinal artery hypo/nonperfusion and insufficiency. Paracentral acute middle maculopathy may represent the earliest form of ischemia in the central macular region, occurring after a milder vascular insult.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Fluorescein Angiography
  • Humans
  • Macular Degeneration* / chemically induced
  • Macular Degeneration* / diagnostic imaging
  • Male
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors* / adverse effects
  • Retinal Diseases* / chemically induced
  • Retinal Diseases* / diagnostic imaging
  • Tomography, Optical Coherence

Substances

  • Phosphodiesterase 5 Inhibitors